The Association Between S100A8/A9 and the Development of Very Late Stent Thrombosis in Patients With Acute Myocardial
Xiang Wang1, Meng Guan2, Xiuhang Zhang3
1Department of Cardiovascular Disease Center, The First Hospital of Jilin University, Jilin University, Jilin, People's Republic of China.
Insights
Very late stent thrombosis (VLST) is a serious complication after percutaneous coronary intervention. Higher S100A8/A9 protein levels are linked to VLST development, indicating its role in thrombosis.
Area of Science:
- Cardiology
- Biochemistry
- Inflammation Research
Background:
- Very late stent thrombosis (VLST) is a rare but severe complication post-percutaneous coronary intervention (PCI).
- The S100A8/A9 protein complex is implicated in thrombotic processes by influencing inflammatory responses.
Purpose of the Study:
- To investigate the association between serum S100A8/A9 levels and the occurrence of VLST.
- To compare S100A8/A9 changes in patients with VLST versus those with acute myocardial infarction (AMI) without VLST.
Main Methods:
- Observational study involving 56 VLST patients, 56 AMI patients, and 112 normal controls.
- Blood samples collected during index PCI and at VLST diagnosis or follow-up angiography.
- Serum S100A8/A9 and high-sensitivity C-reactive protein (hs-CRP) levels were measured and compared.
Main Results:
- S100A8/A9 levels significantly increased from index PCI to VLST diagnosis (3754.4 ± 1688.9 to 5517.8 ± 2650.9 ng/mL).
- In contrast, S100A8/A9 levels decreased in the AMI group post-index PCI (2434.9 ± 1243.4 to 1568.2 ± 772.1 ng/mL), similar to normal controls.
- The increase in S100A8/A9 during VLST was distinct from hs-CRP changes.
Conclusions:
- Elevated serum S100A8/A9 levels are associated with the development of very late stent thrombosis.
- S100A8/A9 may serve as a potential biomarker for predicting VLST risk following PCI.
Abstract:
Very late stent thrombosis (VLST) is a rare but serious complication following percutaneous coronary intervention (PCI). S100A8/A9 plays an important role in thrombosis through modulating the inflammatory response. This observational study aimed to reveal the association between S100A8/A9 and VLST. Continuous blood samples were collected from patients at both the time of index PCI for acute myocardial infarction (AMI) and the time of PCI for VLST (VLST group) or follow-up coronary angiography (AMI group). In all, 56 patients were selected in each group from a cohort of 8476 patients and other 112 individuals who underwent health checkups (normal control [NC] group) were selected as controls. Serum levels of S100A8/A9 and high sensitivity C-reactive protein (hs-CRP) were tested and compared. The mean level of S100A8/A9 was 3754.4 ± 1688.9 ng/mL during index PCI and increased to 5517.8 ± 2650.9 ng/mL at the time of VLST; in the AMI group, S100A8/A9 level was 2434.9 ± 1243.4 ng/mL during index PCI and decreased to 1568.2 ± 772.1 ng/mL during follow-up, similar to that detected in the NC group (1618.2 ± 641.4 ng/mL). Of note, S100A8/A9 levels showed significant increases during VLST when compared to its own levels during index PCI, which was different from the changes of hs-CRP. Higher serum levels of S100A8/A9 are associated with the development of VLST.
Related Concept Videos
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies